Failure of anti-EGFR therapy in p16-positive head and neck cancer – Authors' reply
- 1 October 2013
- journal article
- Published by Elsevier in The Lancet Oncology
- Vol. 14 (11) , e437-e438
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trialThe Lancet Oncology, 2013
- Expression of EGFR, VEGF, and NOTCH1 Suggest Differences in Tumor Angiogenesis in HPV-Positive and HPV-Negative Head and Neck Squamous Cell CarcinomaHead and Neck Pathology, 2013
- Molecular profile of head and neck squamous cell carcinomas bearing p16 high phenotypeAnnals of Oncology, 2013
- Nuclear epidermal growth factor receptor and p16 expression in head and neck squamous cell carcinomaThe Laryngoscope, 2012
- Relationship between Epidermal Growth Factor Receptor Status, p16INK4A, and Outcome in Head and Neck Squamous Cell CarcinomaCancer Epidemiology, Biomarkers & Prevention, 2011